Hubei Huisheng Biotechnology Co., Ltd. announced that it will receive CNY 700 million in an equity round of funding through capital increase from retuning investor Hvsen Biotechnology Co., Ltd. to retain 100% stake in the company on October 25, 2022. After the completion of this capital increase, the registered capital of will be increased from CNY 300 million to CNY 1,000 million. The transaction has been approved at the 28th meeting of the second board of directors and the 23rd meeting of the second board of supervisors and does not need to be submitted to the company's general meeting of shareholders for consideration.